Dr. Qingxi (Charles) Wang, PhD, Chairman & CEO

Dr. Qingxi (Charles) Wang has been the President and CEO of Conjupro Biotherapeutics Inc. since 2016.  He serves as the Executive Director on the Board and Executive President of CSPC Pharmaceutical Group, Ltd. Dr. Wang holds a PhD in Chemistry from the University of Connecticut, and an MBA from Temple University. Prior to joining the Group, Dr. Wang worked at Merck & Co., Inc. in the U.S. for over 20 years, where he held senior positions including Director of Pharmaceutical R&D and Managing Director of Business Development and Operation.

Steven Novick, MD, PhD, Vice President

Steven Novick, MD, PhD, is Vice President, Clinical Development at Conjupro. Steve is a trained medical oncologist, with extensive experience in clinical development, including small molecules and cell therapies. His work has included phase I-II first-in-human studies, proof-of-concept studies, and later stage phase III pivotal clinical studies leading to marketing approval, as well as phase IV post-marketing commitment studies, across both solid tumors and hematologic malignancies. These projects include both large pharma and biotech experience (Roche, Johnson and Johnson, Novartis, BMS, Celgene, Genta). He also has experience in global regulatory strategies, good clinical practice (GCP), and drug safety and pharmacovigilance, with numerous interactions with regulatory authorities, both at FDA an EMA.

Dr. Novick obtained a combined MD-PhD degree from New York University School of Medicine, where he led the initial studies for the identification of a novel oncogene, RSC. He completed a fellowship in phase 1 drug development at Memorial Sloan-Kettering Cancer Center prior to entering the industry.

Xi-De Wang, Ph.D., RAC, VP of Regulatory Science & Compliance

Xi-De has nearly 20 years of experience in the biotechnology and pharmaceutical industries. After obtaining his Ph.D. degree from Michigan State University, Dr. Wang joined Genentech as postdoctoral scientist in the molecular oncology department. Later on he joined Bristol Myers Squibb translational/early clinical development as oncology biomarker lead, responsible for biomarker programs of Sprycel and several other early clinical programs. Prior to joining Conjupro in 2018 as Head of regulatory, he was at BMS and then at Chugai-USA regulatory departments supporting global and US regulatory applications for Sprycel, Opdivo, Bydureon Pen, Eliquis, Hemlibra and several early programs in different therapeutic areas.

John Adamou, MS, MBA, Chief Business Officer

Mr. Adamou has served as our Chief Business Officer since October 2021. Mr. Adamou has over 25 years of business development, strategic transactions, and scientific experience in the biotechnology and pharmaceutical industry at BeiGene, rHEALTH, Boehringer Ingelheim Pharmaceuticals and Medlmmune. Mr. Adamou has an established track-record of signed deals and significant experience with a broad array of deal structures across various therapeutic categories including, platform technologies, R&D collaborations, co-developments, commercialization alliances, IP licenses, equity investments, and out-licensing arrangements.

Mr. Adamou began his business development career in 2000 at MedImmune and earlier in his career Mr. Adamou also held various research roles with increasing responsibility with MedImmune, SmithKline Beecham Pharmaceuticals, and Allelix Biopharmaceuticals.

Mr. Adamou holds B.S. and M.S. degrees in Molecular Biology and Genetics from the University of Guelph, Canada, and an M.B.A from the Keller Graduate School of Management.